Jardiance

(Empagliflozin)

ApprovedSmall molecule

Empagliflozin is used to treat type 2 diabetes by helping the kidneys remove excess sugar through urine, and it also helps protect the heart and kidneys in patients with diabetes or heart disease.[2] Jardiance is currently approved and in use across 79 indications[4].[1]

Jardiance is one of 1207 small molecule programs targeting Myocardial Infarction. It is currently in Approved.

Indications

408

Total Trials

Active Trials

1,206

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Myocardial InfarctionActive, not recruiting

Type 2 Diabetes MellitusCompleted

Heart FailureUnknown status

Type 2 DiabetesUnknown status

Coronary Artery DiseaseUnknown status

InteractionCompleted

EmpagliflozinUnknown status

NephrolithiasisApproved

Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IAApproved

Glycogen Storage Disease Due to Glucose-6-Phosphatase DeficiencyApproved

Myocardial InfarctionPhase 3

Active, not recruiting

Type 2 Diabetes MellitusApproved

Completed

Heart FailureApproved

Unknown status

Type 2 DiabetesApproved

Unknown status

Coronary Artery DiseaseApproved

Unknown status

InteractionPhase 1

Completed

EmpagliflozinApproved

Unknown status

NephrolithiasisApproved

Approved

Glycogen Storage Disease Due to Glucose-6-Phosphatase Deficiency Type IAApproved

Approved

Glycogen Storage Disease Due to Glucose-6-Phosphatase DeficiencyApproved

Approved

Showing 10 of 78 indications

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Approved

42 2

Amidate

Pfizer

Preclinical

1 3

Brethine

Sanofi

Preclinical

1 4

Zemplar

Adriamycin

Xifaxan

2 7

Potassium Iodide

MMeda Pharmaceuticals

Preclinical

1 8

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 9

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Hypertrophic Cardiomyopathy

NCT05182658

Phase 3Recruiting

Schizophrenia

NCT05669742

Phase 2Recruiting

Trial

NCT06570473

Phase 1Recruiting

Pulmonary Arterial Hypertension

NCT06554301

Post-ApprovalNot yet recruiting

Type 2 Diabetes Mellitus

NCT07311551

Phase 2/3Active, not recruiting

Cystic Fibrosis

NCT06149793

Clinical

Trials by Indication[1]

Empagliflozin55 trials

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01867307·39 enrolled

Emp-Activity: Empagliflozin Functional Capacity

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05350202·3,431 enrolled

Pharmacokinetic Evaluation of Empagliflozin

Completed·—·Phase 1·NCT03059056·6 enrolled

Show 52 more trials

Characteristics of Empagliflozin Initiators

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03050619·31,908 enrolled

Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01672788·36 enrolled

Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01811953·48 enrolled

Pharmacokinetics of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed·HHandok Inc.·Phase 1·NCT06339788·40 enrolled

A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT05083949·32 enrolled

Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin

Unknown status· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 1·NCT02854748·30 enrolled

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study

Recruiting·GGetz Pharma·Phase 4·NCT05164263·2,000 enrolled

Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics

Completed·JJohannes Gutenberg University Mainz·Phase 4·NCT02932436·144 enrolled

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Completed·—·Phase 3·NCT05036421·18 enrolled

Empagliflozin and Red Blood Cell 2,3-biphosphoglycerate Levels

Unknown status·—··NCT06284850·40 enrolled

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Completed·GGenuine Research Center, Egypt·Phase 1·NCT05132023·26 enrolled

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07213895·14 enrolled

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02106923·72 enrolled

Empagliflozin 10 mg Tablets Relative to Jardiance 10 mg

Unknown status·BBio-innova Co., Ltd·Phase 1·NCT06232239·26 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06792968·64 enrolled

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07266766·40 enrolled

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT03766724·42 enrolled

Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT06932159·40 enrolled

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Completed·MMutah University·N/A·NCT05229796·26 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 5 mg/850 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy® 5 mg/850 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06766500·64 enrolled

Pharmacokinetics and Safety of HD-P023 and Co-administration of Teneligliptin and Empagliflozin High in Healthy Volunteers

Completed·HHandok Inc.·Phase 1·NCT06889350·40 enrolled

Pharmacokinetics and Bioequivalence Study of Empagliflozin+Metformin Hydrochloride 12.5 mg/1000 mg Film-coated Tablets (Gedeon Richter Plc., Hungary) Versus Synjardy 12.5 mg/1000 mg Film-coated Tablets (Boehringer Ingelheim International GmbH, Germany)

Completed·GGedeon Richter Plc.·Phase 1·NCT06823856·64 enrolled

Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fast Condition

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07372118·32 enrolled

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01975220·72 enrolled

Empagliflozin in ESKD - A Feasibility Study

Recruiting·UUniversity of Mississippi Medical Center·Phase 1/2·NCT05687058·24 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02758171·56 enrolled

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02632747·31 enrolled

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Completed·HHandok Inc.·Phase 1·NCT04431141·32 enrolled

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01844531·24 enrolled

Empagliflozin vs Metformin in PCOS

Completed·HHull University Teaching Hospitals NHS Trust·Phase 2/3·NCT03008551·40 enrolled

Empagliflozin and Cardiac Remodelling in People Without Diabetes

Completed·UUnity Health Toronto·Phase 4·NCT04461041·169 enrolled

EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03594110·6,609 enrolled

Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

Unknown status·HHong Kong Children's Hospital··NCT04986735·11 enrolled

Empagliflozin in Adolescent Diabetes

Withdrawn·OOhio State University·Phase 4·NCT04917692

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02266472·30 enrolled

Gemigliptin, Dapagliflozin, Empagliflozin DDI Study

Unknown status·LLG Chem·Phase 1·NCT03565458·48 enrolled

This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03629054·30 enrolled

Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Completed·UUniversity of Utah·Phase 1·NCT05614115·62 enrolled

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02580591·977 enrolled

Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics

Unknown status·—·Phase 4·NCT01001962·1,054 enrolled

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

Completed·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT03485222·84 enrolled

Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT02874807·88 enrolled

Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02577315·25 enrolled

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Completed·—··NCT03748810·600 enrolled

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin

Recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT07331389·111 enrolled

This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT03259490·30 enrolled

Empagliflozin and Sympathetic Nerve Traffic

Completed·PProfil Institut für Stoffwechselforschung GmbH·Phase 4·NCT03254849·75 enrolled

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04295005·24,500 enrolled

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

Active, not recruiting·CConrado Roberto Hoffmann Filho·Phase 3·NCT06683053·90 enrolled

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

Unknown status·SSeoul National University Bundang Hospital·Phase 4·NCT05140694·135 enrolled

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03429543·175 enrolled

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02230995·30 enrolled

Type 2 Diabetes18 trials

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05444153

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT04531462·129 enrolled

Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes

Completed·TThe Deutsche Diabetes Forschungsgesellschaft e.V.·Phase 4·NCT02637973·84 enrolled

Show 15 more trials

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes

Recruiting·KKarolinska Institutet·N/A·NCT05501483·60 enrolled

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Completed·MMedanta, The Medicity, India·N/A·NCT02686476·100 enrolled

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01734785·607 enrolled

Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes

Completed·IInstitut für Pharmakologie und Präventive Medizin·Phase 3·NCT02752113·101 enrolled

Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes

Unknown status·UUnity Health Toronto·Phase 4·NCT02998970·97 enrolled

Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes

Completed·RRWTH Aachen University·Phase 2·NCT03132181·40 enrolled

Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01984606

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin

Active, not recruiting·CCelltrion·Phase 3·NCT06571591·582 enrolled

Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2 Diabetes on a Background of Alogliptin and Metformin

Recruiting·CCelltrion·Phase 3·NCT07093476·171 enrolled

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Unknown status·MMetacrine, Inc.·Phase 2·NCT04702490·120 enrolled

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Withdrawn· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06083675

The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes

Unknown status·UUniversity of Malaya·Phase 4·NCT02964715·25 enrolled

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03993132·26,774 enrolled

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04233801·219 enrolled

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04098575·9,571 enrolled

Heart Failure18 trials

Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease

Recruiting·NNational Taiwan University Hospital·Phase 4·NCT06249932·95 enrolled

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04937816·16,746 enrolled

Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure

Recruiting·UUniversity of Minnesota·Phase 1·NCT06507657·80 enrolled

Show 15 more trials

EMPA Acute Heart Failure

Terminated·RRWTH Aachen University·Phase 2·NCT03554200·19 enrolled

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT05139472·8 enrolled

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Completed·YYale University·Phase 1·NCT03027960·21 enrolled

Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Unknown status·ZZhijun Sun·Phase 4·NCT05600387·100 enrolled

Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients

Unknown status·RRambam Health Care Campus·Phase 4·NCT03271879·128 enrolled

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

Completed·SSaint Luke's Health System·Phase 4·NCT03030222·65 enrolled

Empagliflozin in Heart Failure Dialysis Patients

Completed·SShahid Beheshti University of Medical Sciences·N/A·NCT05967156·30 enrolled

Empagliflozin in Acute Heart Failure

Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT05305495·25 enrolled

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03057951·5,988 enrolled

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03332212·72 enrolled

Canagliflozin in Patients With Acute Decompansted Heart Failure

Completed·OOctober 6 University·Phase 3·NCT05364190·142 enrolled

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03448406·315 enrolled

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT03057977·3,730 enrolled

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04157751·530 enrolled

Add-on Diuretics in Acute Decompensated Heart Failure

Recruiting·TTanta University·Phase 2·NCT07372040·66 enrolled

Type 2 Diabetes Mellitus17 trials

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Terminated· Novartis logo

Novartis·Phase 2·NCT03152552·125 enrolled

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT02863328·822 enrolled

Show 14 more trials

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05130463·1,053 enrolled

Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus

Unknown status·CCentro Universitario de Ciencias de la Salud, Mexico·Phase 3·NCT04195243·24 enrolled

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02182830·166 enrolled

Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus

Completed·—·Phase 3·NCT06952231·50 enrolled

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02453555·275 enrolled

A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)

Not yet recruiting·—·Phase 4·NCT07311551·112 enrolled

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02121483·27 enrolled

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03249506·25,358 enrolled

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT04014192·40 enrolled

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02489968·880 enrolled

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Completed·GGetz Pharma·Phase 4·NCT05359432·120 enrolled

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02589639·269 enrolled

Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

Completed·LLexicon Pharmaceuticals·Phase 3·NCT03351478·770 enrolled

To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05162014·494,679 enrolled

Diabetes Mellitus7 trials

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT05028140·480 enrolled

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Completed·GGetz Pharma·Phase 4·NCT04665284·244 enrolled

Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.

Recruiting·EEMS·Phase 3·NCT04602754·228 enrolled

Show 4 more trials

Efficacy and Safety of Egito Association in the Treatment of Type II Diabetes Mellitus and Hypertension

Withdrawn·EEMS·Phase 3·NCT04970108

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Recruiting·EEMS·Phase 3·NCT04670666·270 enrolled

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions

Completed·RResearch Institute for Complex Problems of Cardiovascular Diseases, Russia·Phase 4·NCT04497792·40 enrolled

Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

Unknown status·EEMS·Phase 3·NCT04603508·240 enrolled

67 more indications

Type 1 Diabetes Mellitus3 trials

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02414958·730 enrolled

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01969747·75 enrolled

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02702011·48 enrolled

Chronic Kidney Disease3 trials

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

Not yet recruiting·IInstituto de Investigación Biomédica de Salamanca··NCT07348484·300 enrolled

Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression

Completed·TTanta University·Phase 2/3·NCT05373680·118 enrolled

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05465317·62,197 enrolled

Neutropenia3 trials

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT05078879·4 enrolled

Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency

Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT04138251·5 enrolled

Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia

Unknown status·CChildren's Memorial Health Institute, Poland·Phase 2·NCT04930627·20 enrolled

Hypoglycemia3 trials

Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes

Withdrawn·UUniversity Hospital, Basel, Switzerland·Phase 2·NCT05174507

Empagliflozin for the Treatment of Postprandial Hypoglycemia

Terminated·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT05036317·40 enrolled

Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study

Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT03200782·12 enrolled

Hypertension2 trials

SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Completed·JJichi Medical University·Phase 4·NCT03050229·174 enrolled

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Completed· Sanofi logo

Sanofi·Phase 2·NCT03462069·41 enrolled

Trial2 trials

Feasibility Trial for a Right Ventricular Failure Platform Trial

Recruiting·UUniversity of Alberta·Phase 2·NCT06570473·30 enrolled

SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT05138575·53 enrolled

SGLT-2 Inhibitor2 trials

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Completed·SSadat City University·N/A·NCT05359341·175 enrolled

SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.

Completed·UUniversity of Leicester·Phase 4·NCT02798744·68 enrolled

Fasting Conditions2 trials

To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.

Completed·HHumanis Saglık Anonim Sirketi·Phase 1·NCT07039890·40 enrolled

Investigation of the Effect of Food on the Bioavailability of a 25 mg Empagliflozin Tablet as Well as Assessment of Dose Proportionality Between 10 mg and 25 mg Empagliflozin Tablets Under Fasting Conditions.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01451775·18 enrolled

Kidney Transplant2 trials

CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Terminated·—·Phase 2·NCT04906213·20 enrolled

Empagliflozin Treatment in Kidney Transplant Recipients

Recruiting·VVA Office of Research and Development·Phase 4·NCT06013865·264 enrolled

Cardiovascular Disease2 trials

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT04927858·460,558 enrolled

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT05102071

Autosomal Dominant Polycystic Kidney Disease2 trials

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT05510115·50 enrolled

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

Recruiting·—·Phase 2·NCT06435858·40 enrolled

MPA1 trial

Empa/Lina FDC Food Effect Study (Japan)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02815644·22 enrolled

Cystic Fibrosis1 trial

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Active, not recruiting·UUniversity of Minnesota·Phase 2/3·NCT06149793·8 enrolled

Diabetes1 trial

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

Completed·—··NCT04215536·103,752 enrolled

Treatment1 trial

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03807440·4,083 enrolled

Transplant Recipient1 trial

Randomized Trial of SGLT2i in Heart Transplant Recipients

Recruiting·VVA Office of Research and Development·Phase 4·NCT06625073·200 enrolled

Schizophrenia1 trial

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients

Recruiting·TTanta University·Phase 3·NCT05669742·40 enrolled

Renal Transplant Recipients1 trial

Empagliflozin in Renal Transplant Recipients

Completed·OOslo University Hospital·Phase 4·NCT03157414·49 enrolled

Elderly1 trial

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial

Unknown status·CCenter for Outcomes Research and Clinical Epidemiology, Italy·Phase 4·NCT04796428·1,167 enrolled

Myocardial Infarction1 trial

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT04509674·6,522 enrolled

Cardiomyopathy1 trial

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Unknown status·HHuashan Hospital·N/A·NCT04520646·10 enrolled

High Cardiovascular Risk1 trial

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

Completed·CCaroline M Kistorp·Phase 3·NCT03151343·92 enrolled

Arterial Stiffness1 trial

Empagliflozin Reversal of Arterial StiffnEss in Aging

Recruiting·UUniversity of Missouri-Columbia·Phase 2/3·NCT06506422·80 enrolled

Chronic Hepatitis1 trial

Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients

Active, not recruiting·TThe University of Hong Kong·Phase 4·NCT05147090·106 enrolled

Hypertrophic Cardiomyopathy1 trial

Empagliflozin in Hypertrophic Cardiomyopathy

Active, not recruiting·NNational Institute of Cardiology, Warsaw, Poland·Phase 3·NCT05182658·250 enrolled

Polycystic Ovary Syndrome1 trial

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

Unknown status·—·Phase 4·NCT05200793·75 enrolled

Pulmonary Arterial Hypertension1 trial

A Study on the Efficacy and Safety of Empagliflozin in the Treatment of Pulmonary Arterial Hypertension

Recruiting·CChina National Center for Cardiovascular Diseases·Phase 1·NCT06554301·72 enrolled

Safety and Efficacy1 trial

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Unknown status·IInstituto Nacional de Cardiologia Ignacio Chavez·Phase 2/3·NCT05580510·160 enrolled

Cardiovascular1 trial

Cardiovascular Effects of Empagliflozine

Unknown status·TTel Aviv University·N/A·NCT02918591·10 enrolled

Hyperglycemia1 trial

Variable Effects of Anti-diabetics on Stress Hyperglycemia Ratio

Completed·UUniversity of Diyala··NCT05822674·80 enrolled

T2DM1 trial

Glycemic Variability of Combination Therapies in T2DM

Recruiting·JJW Pharmaceutical·Phase 4·NCT07442006·178 enrolled

Mitral regurgitation1 trial

ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling

Recruiting·RRehab Werida··NCT07379788·180 enrolled

Hyponatremia1 trial

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Completed·UUniversity Hospital, Basel, Switzerland·Phase 2/3·NCT02729766·15 enrolled

Cardiac1 trial

Impact of Empaglifozine on Cardiac Ectopic Fat

Completed·AAssistance Publique Hopitaux De Marseille·Phase 3·NCT03118336·56 enrolled

Completed·UUniversity of Pisa··NCT04735042·60 enrolled

Non-Alcoholic Steatohepatitis1 trial

Reducing Non-Alcoholic Steatohepatitis

Enrolling by invitation·MMilitary University Hospital, Prague·N/A·NCT06519448·30 enrolled

Congestive Heart Failure1 trial

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial

Unknown status·UUniversity Health Network, Toronto·Phase 2·NCT04535960·36 enrolled

Rheumatoid Arthritis1 trial

The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate

Not yet recruiting·TTanta University·Phase 4·NCT06641128·44 enrolled

Injury1 trial

Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCI

Unknown status·—·N/A·NCT03591991·128 enrolled

Medication1 trial

Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)

Completed·NNational and Kapodistrian University of Athens··NCT05946148·78 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease

Not yet recruiting·—·Phase 4·NCT07180745·400 enrolled

Urinary Tract Infection1 trial

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT03764631·1,502 enrolled

Drug1 trial

Cognitive Protective Effect of Newer Antidiabetic Drugs

Unknown status·—··NCT05347459·100 enrolled

Cardiotoxicity1 trial

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT06844669·7 enrolled

Coronary Artery Disease1 trial

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Completed·CCHEOL WHAN LEE, M.D., Ph.D·Phase 4·NCT03208465·100 enrolled

Female1 trial

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02782624·16 enrolled

Liver Disease1 trial

Antidiabetic Drugs for Steatotic Liver Disease

Completed·YYonsei University·Phase 4·NCT03646292·51 enrolled

Stroke1 trial

EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source

Recruiting·UUniversity of East Anglia·Phase 2/3·NCT06715449·100 enrolled

Atrial Fibrillation1 trial

Empagliflozin and Atrial Fibrillation Treatment

Unknown status·—·Phase 4·NCT04583813·400 enrolled

Nephrotic Syndrome1 trial

SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

Active, not recruiting·MMansoura University·Phase 2/3·NCT07214818·75 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Empagliflozin in NODAT

Terminated·RRenJi Hospital·Phase 4·NCT03642184·6 enrolled

Aortic Valve Replacement1 trial

EMPagliflozin After Aortic Valve Replacement

Active, not recruiting·RRigshospitalet, Denmark·Phase 4·NCT06171802·205 enrolled

MODY1 trial

Impact of SGLT2 on Glucosuria in HNF1A-MODY

Completed·SSteno Diabetes Center Copenhagen·N/A·NCT05417646·21 enrolled

Peritoneal Dialysis1 trial

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Recruiting·UUniversity Health Network, Toronto·Phase 3·NCT05715814·20 enrolled

Interaction1 trial

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Completed·CChipscreen Biosciences, Ltd.·Phase 1·NCT05681273·48 enrolled

Fatty Liver1 trial

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Unknown status·GGetz Pharma·Phase 4·NCT04976283·123 enrolled

Diabetic Ketoacidosis1 trial

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02864914·333,580 enrolled

Microvascular Circulation1 trial

Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Completed·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT02471963·74 enrolled

Kidney Disease1 trial

Empaglifozin in Early Diabetic Kidney Disease

Withdrawn·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT03173963

Antithrombotic1 trial

Antithrombotic Activities of Sotagliflozin vs. Empagliflozin

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 4·NCT06618976·17 enrolled

Advanced1 trial

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Withdrawn·NNorthwell Health·Phase 4·NCT02768220

COVID-191 trial

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Adiposity1 trial

Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02833415·40 enrolled

Type 1 Diabetes1 trial

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 4·NCT06021145·46 enrolled

Unspecified4 trials

Pharmacological Reduction of Right Ventricular Enlargement

Completed·—·Phase 3·NCT04345796·56 enrolled

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Completed·NNational Institute on Aging (NIA)·Phase 1·NCT03852901·21 enrolled

The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors

Completed·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT02792400·24 enrolled

Show 1 more trial

SGLT2 Inhibition and Left Ventricular Mass

Terminated·HHannover Medical School·Phase 4·NCT02728453·7 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 1, 2014

JARDIANCE

NDA NDA204629

Sources

References

[1]
ClinicalTrials.gov — 408 trial records for Empagliflozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Jardiance drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Empagliflozin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Empagliflozin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA204629). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Jardiance. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Sodium/glucose Cotransporter 2 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

Patent Landscape[6]

Patent Cliff

Oct 15, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7713938*PEDOct 15, 2027

7579449*PEDFeb 1, 2029

12115179Feb 11, 2030

8551957*PEDApr 14, 2030

12115179*PEDAug 11, 2030

11 more patents

12527810*PEDOct 22, 2033

11813275Apr 3, 2034

12263153Apr 3, 2034

9949997May 17, 2034

11833166*PEDOct 3, 2034

10258637*PEDOct 3, 2034

11813275*PEDOct 3, 2034

11090323*PEDOct 3, 2034

12433906*PEDOct 3, 2034

9949997*PEDNov 17, 2034

9949998*PEDDec 11, 2034

Jardiance

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Empagliflozin55 trials

Type 2 Diabetes18 trials

Heart Failure18 trials

Type 2 Diabetes Mellitus17 trials

Diabetes Mellitus7 trials

Type 1 Diabetes Mellitus3 trials

Chronic Kidney Disease3 trials

Neutropenia3 trials

Hypoglycemia3 trials

Hypertension2 trials

Trial2 trials

SGLT-2 Inhibitor2 trials

Fasting Conditions2 trials

Kidney Transplant2 trials

Cardiovascular Disease2 trials

Autosomal Dominant Polycystic Kidney Disease2 trials

MPA1 trial

Cystic Fibrosis1 trial

Diabetes1 trial

Treatment1 trial

Transplant Recipient1 trial

Schizophrenia1 trial

Renal Transplant Recipients1 trial

Elderly1 trial

Myocardial Infarction1 trial

Cardiomyopathy1 trial

High Cardiovascular Risk1 trial

Arterial Stiffness1 trial

Chronic Hepatitis1 trial

Hypertrophic Cardiomyopathy1 trial

Polycystic Ovary Syndrome1 trial

Pulmonary Arterial Hypertension1 trial

Safety and Efficacy1 trial

Cardiovascular1 trial

Hyperglycemia1 trial

T2DM1 trial

Mitral regurgitation1 trial

Hyponatremia1 trial

Cardiac1 trial

Weight loss1 trial

Cirrhosis1 trial

Inflammation1 trial

Non-Alcoholic Steatohepatitis1 trial

Congestive Heart Failure1 trial

Rheumatoid Arthritis1 trial

Injury1 trial

Medication1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Urinary Tract Infection1 trial

Drug1 trial

Cardiotoxicity1 trial

Coronary Artery Disease1 trial

Female1 trial

Liver Disease1 trial

Stroke1 trial

Atrial Fibrillation1 trial

Nephrotic Syndrome1 trial

Efficacy and Safety1 trial

Aortic Valve Replacement1 trial

MODY1 trial

Peritoneal Dialysis1 trial

Interaction1 trial

Fatty Liver1 trial

Diabetic Ketoacidosis1 trial

Microvascular Circulation1 trial

Kidney Disease1 trial

Antithrombotic1 trial

Advanced1 trial

COVID-191 trial

Adiposity1 trial

Type 1 Diabetes1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References